image
Healthcare - Medical - Diagnostics & Research - NYSE - US
$ 160.44
2.3 %
$ 17.9 B
Market Cap
21.59
P/E
1. INTRINSIC VALUE

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals.[ Read More ]

The intrinsic value of one DGX stock under the base case scenario is HIDDEN Compared to the current market price of 160 USD, Quest Diagnostics Incorporated is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart DGX

image
FINANCIALS
9.25 B REVENUE
-6.38%
1.26 B OPERATING INCOME
-11.62%
850 M NET INCOME
-16.26%
1.27 B OPERATING CASH FLOW
-25.96%
-1.06 B INVESTING CASH FLOW
-95.40%
160 M FINANCING CASH FLOW
109.24%
2.49 B REVENUE
3.80%
330 M OPERATING INCOME
-10.81%
237 M NET INCOME
3.95%
356 M OPERATING CASH FLOW
-1.11%
-1.63 B INVESTING CASH FLOW
-716.50%
1.77 B FINANCING CASH FLOW
587.60%
Balance Sheet Decomposition Quest Diagnostics Incorporated
image
Current Assets 2.37 B
Cash & Short-Term Investments 686 M
Receivables 1.21 B
Other Current Assets 476 M
Non-Current Assets 11.6 B
Long-Term Investments 135 M
PP&E 2.42 B
Other Non-Current Assets 9.1 B
Current Liabilities 1.82 B
Accounts Payable 378 M
Short-Term Debt 585 M
Other Current Liabilities 852 M
Non-Current Liabilities 5.79 B
Long-Term Debt 4.91 B
Other Non-Current Liabilities 876 M
EFFICIENCY
Earnings Waterfall Quest Diagnostics Incorporated
image
Revenue 9.25 B
Cost Of Revenue 6.29 B
Gross Profit 2.96 B
Operating Expenses 1.61 B
Operating Income 1.26 B
Other Expenses 412 M
Net Income 850 M
RATIOS
32.00% GROSS MARGIN
32.00%
13.64% OPERATING MARGIN
13.64%
9.23% NET MARGIN
9.23%
13.54% ROE
13.54%
6.09% ROA
6.09%
8.84% ROIC
8.84%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Quest Diagnostics Incorporated
image
Net Income 850 M
Depreciation & Amortization 439 M
Capital Expenditures -408 M
Stock-Based Compensation 77 M
Change in Working Capital -145 M
Others 25 M
Free Cash Flow 864 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Quest Diagnostics Incorporated
image
Wall Street analysts predict an average 1-year price target for DGX of $165 , with forecasts ranging from a low of $144 to a high of $185 .
DGX Lowest Price Target Wall Street Target
144 USD -10.25%
DGX Average Price Target Wall Street Target
165 USD 2.79%
DGX Highest Price Target Wall Street Target
185 USD 15.31%
4. DIVIDEND ANALYSIS
0.48% DIVIDEND YIELD
0.75 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Quest Diagnostics Incorporated
image
Sold
0-3 MONTHS
8.52 M USD 3
3-6 MONTHS
60.1 K USD 1
6-9 MONTHS
2.31 M USD 4
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 week ago
Nov 06, 2024
Sell 321 K USD
DEPPE MICHAEL J
SVP, Corp. Controller & CAO
- 2100
152.7029 USD
1 week ago
Nov 06, 2024
Sell 370 K USD
DEPPE MICHAEL J
SVP, Corp. Controller & CAO
- 2400
153.9829 USD
1 week ago
Nov 06, 2024
Sell 640 K USD
DEPPE MICHAEL J
SVP, Corp. Controller & CAO
- 4135
154.736 USD
1 week ago
Nov 06, 2024
Sell 397 K USD
DEPPE MICHAEL J
SVP, Corp. Controller & CAO
- 2600
152.7115 USD
1 week ago
Nov 06, 2024
Sell 359 K USD
DEPPE MICHAEL J
SVP, Corp. Controller & CAO
- 2331
154.031 USD
1 week ago
Nov 06, 2024
Sell 803 K USD
DEPPE MICHAEL J
SVP, Corp. Controller & CAO
- 5189
154.7424 USD
2 weeks ago
Oct 28, 2024
Sell 279 K USD
KUPPUSAMY KARTHIK
SVP, Clinical Solutions
- 1775
156.9156 USD
2 months ago
Aug 29, 2024
Sell 5.04 M USD
PREVOZNIK MICHAEL E
SVP & General Counsel
- 32551
154.9727 USD
2 months ago
Aug 28, 2024
Sell 305 K USD
KUPPUSAMY KARTHIK
SVP, Clinical Solutions
- 1990
153.2612 USD
3 months ago
Jul 24, 2024
Sell 60.1 K USD
DELANEY MARK E
SVP & Chief Commercial Officer
- 420
143.08 USD
6 months ago
Apr 29, 2024
Sell 246 K USD
KUPPUSAMY KARTHIK
SVP, Clinical Solutions
- 1760
140 USD
8 months ago
Feb 28, 2024
Sell 703 K USD
Doherty Catherine T.
EVP, Regional Businesses
- 5557
126.57 USD
8 months ago
Feb 29, 2024
Sell 149 K USD
Doherty Catherine T.
EVP, Regional Businesses
- 1187
125.88 USD
8 months ago
Feb 29, 2024
Sell 706 K USD
PREVOZNIK MICHAEL E
SVP & General Counsel
- 5611
125.88 USD
8 months ago
Feb 22, 2024
Sell 83.4 K USD
PREVOZNIK MICHAEL E
SVP & General Counsel
- 661
126.14 USD
8 months ago
Feb 23, 2024
Sell 317 K USD
Gregg Vicky B
Director
- 2500
126.6386 USD
8 months ago
Feb 22, 2024
Sell 104 K USD
Doherty Catherine T.
EVP, Regional Businesses
- 821
126.14 USD
1 year ago
Mar 07, 2023
Sell 668 K USD
PREVOZNIK MICHAEL E
SVP & General Counsel
- 4754
140.55 USD
1 year ago
Mar 07, 2023
Sell 746 K USD
Doherty Catherine T.
SVP, Regional Businesses
- 5307
140.55 USD
1 year ago
Mar 03, 2023
Sell 101 K USD
Doherty Catherine T.
SVP, Regional Businesses
- 717
140.63 USD
1 year ago
Mar 02, 2023
Sell 82.2 K USD
PREVOZNIK MICHAEL E
SVP & General Counsel
- 593
138.54 USD
1 year ago
Feb 24, 2023
Sell 200 K USD
PREVOZNIK MICHAEL E
SVP & General Counsel
- 1415
141.42 USD
1 year ago
Feb 24, 2023
Sell 239 K USD
Doherty Catherine T.
SVP, Regional Businesses
- 1690
141.42 USD
1 year ago
Dec 01, 2022
Sell 309 K USD
RING TIMOTHY M
Director
- 2025
152.5 USD
1 year ago
Nov 28, 2022
Sell 2.58 M USD
Doherty Catherine T.
SVP, Regional Businesses
- 17358
148.9153 USD
1 year ago
Nov 28, 2022
Sell 3.5 M USD
Doherty Catherine T.
SVP, Regional Businesses
- 23407
149.3737 USD
2 years ago
Nov 01, 2022
Sell 288 K USD
RING TIMOTHY M
Director
- 2000
144.06 USD
2 years ago
Oct 26, 2022
Sell 2.25 M USD
DEPPE MICHAEL J
VP, Corp. Controller & CAO
- 15497
145 USD
2 years ago
Oct 03, 2022
Sell 247 K USD
RING TIMOTHY M
Director
- 2000
123.39 USD
2 years ago
Sep 01, 2022
Sell 250 K USD
RING TIMOTHY M
director:
- 2000
125.02 USD
2 years ago
Aug 01, 2022
Sell 272 K USD
RING TIMOTHY M
director:
- 2000
136.04 USD
2 years ago
Jul 01, 2022
Sell 267 K USD
RING TIMOTHY M
director:
- 2000
133.47 USD
2 years ago
May 25, 2022
Sell 1.38 M USD
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
- 9823
140.581 USD
2 years ago
May 25, 2022
Sell 959 K USD
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
- 6821
140.602 USD
2 years ago
May 25, 2022
Sell 584 K USD
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
- 4131
141.348 USD
2 years ago
May 25, 2022
Sell 363 K USD
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
- 2565
141.361 USD
2 years ago
May 25, 2022
Sell 92.5 K USD
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
- 651
142.151 USD
2 years ago
May 25, 2022
Sell 128 K USD
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
- 900
142.134 USD
2 years ago
May 23, 2022
Sell 5.78 M USD
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
- 41268
140.119 USD
2 years ago
May 23, 2022
Sell 4.75 M USD
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
- 33898
140.124 USD
2 years ago
May 23, 2022
Sell 142 K USD
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
- 1000
141.509 USD
2 years ago
May 23, 2022
Sell 113 K USD
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
- 800
141.542 USD
2 years ago
May 23, 2022
Sell 42.7 K USD
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
- 300
142.24 USD
2 years ago
May 23, 2022
Sell 28.5 K USD
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
- 200
142.255 USD
2 years ago
May 24, 2022
Sell 17.7 M USD
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
- 126126
140.12 USD
2 years ago
May 24, 2022
Sell 21.9 M USD
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
- 156282
140.122 USD
2 years ago
May 17, 2022
Sell 7.08 M USD
PREVOZNIK MICHAEL E
SVP & General Counsel
- 50604
139.969 USD
2 years ago
Mar 07, 2022
Sell 842 K USD
PREVOZNIK MICHAEL E
SVP & General Counsel
- 6228
135.21 USD
2 years ago
Mar 07, 2022
Sell 951 K USD
Doherty Catherine T.
SVP, Group Exec. Clin. Fran.
- 7032
135.21 USD
2 years ago
Feb 28, 2022
Sell 85.9 K USD
PREVOZNIK MICHAEL E
SVP & General Counsel
- 661
130 USD
2 years ago
Feb 24, 2022
Sell 347 K USD
Doherty Catherine T.
SVP, Group Exec. Clin. Fran.
- 2750
126.26 USD
2 years ago
Feb 24, 2022
Sell 211 K USD
PREVOZNIK MICHAEL E
SVP & General Counsel
- 1669
126.26 USD
2 years ago
Nov 29, 2021
Sell 46 K USD
Doherty Catherine T.
SVP, Group Exec. Clin. Fran.
- 300
153.383 USD
2 years ago
Nov 29, 2021
Sell 503 K USD
Doherty Catherine T.
SVP, Group Exec. Clin. Fran.
- 3250
154.792 USD
2 years ago
Nov 29, 2021
Sell 550 K USD
Doherty Catherine T.
SVP, Group Exec. Clin. Fran.
- 3532
155.774 USD
2 years ago
Nov 29, 2021
Sell 2.5 M USD
Doherty Catherine T.
SVP, Group Exec. Clin. Fran.
- 15908
156.855 USD
2 years ago
Nov 29, 2021
Sell 2.3 M USD
Doherty Catherine T.
SVP, Group Exec. Clin. Fran.
- 14575
157.533 USD
3 years ago
Jul 28, 2021
Sell 19.6 M USD
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
- 139751
140.141 USD
3 years ago
Jul 29, 2021
Sell 745 K USD
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
- 5300
140.591 USD
3 years ago
Jul 29, 2021
Sell 592 K USD
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
- 4193
141.216 USD
3 years ago
Jul 26, 2021
Sell 814 K USD
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
- 5813
140.03 USD
3 years ago
Jul 27, 2021
Sell 4.59 M USD
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
- 32788
140.007 USD
3 years ago
Jul 27, 2021
Sell 851 K USD
WILENSKY GAIL R
Director
- 6111
139.323 USD
3 years ago
Jul 27, 2021
Sell 851 K USD
WILENSKY GAIL R
Director
- 6111
139.268 USD
3 years ago
May 07, 2021
Sell 1.19 M USD
Doherty Catherine T.
SVP, Group Exec. Clin. Fran.
- 8536
139.963 USD
3 years ago
May 05, 2021
Sell 6.16 M USD
PREVOZNIK MICHAEL E
SVP & General Counsel
- 44939
137 USD
3 years ago
Mar 10, 2021
Sell 671 K USD
PREVOZNIK MICHAEL E
SVP & General Counsel
- 5574
120.47 USD
3 years ago
Feb 25, 2021
Sell 92.5 K USD
PREVOZNIK MICHAEL E
SVP & General Counsel
- 801
115.49 USD
3 years ago
Feb 24, 2021
Sell 51.2 K USD
PREVOZNIK MICHAEL E
SVP & General Counsel
- 438
116.95 USD
3 years ago
Feb 24, 2021
Sell 87.7 K USD
PREVOZNIK MICHAEL E
SVP & General Counsel
- 750
116.95 USD
3 years ago
Dec 24, 2020
Sell 7.11 M USD
GUINAN MARK
Executive Vice President & CFO
- 59193
120.057 USD
3 years ago
Dec 24, 2020
Sell 2.73 M USD
GUINAN MARK
Executive Vice President & CFO
- 22563
121.178 USD
3 years ago
Nov 24, 2020
Sell 770 K USD
WILENSKY GAIL R
Director
- 6111
126.022 USD
3 years ago
Nov 23, 2020
Sell 707 K USD
STANZIONE DANIEL
Director
- 5621
125.7317 USD
3 years ago
Nov 23, 2020
Sell 418 K USD
STANZIONE DANIEL
Director
- 3302
126.4639 USD
3 years ago
Nov 23, 2020
Sell 293 K USD
STANZIONE DANIEL
Director
- 2300
127.4508 USD
4 years ago
Oct 21, 2020
Sell 712 K USD
DEPPE MICHAEL J
VP, Corp. Controller & CAO
- 5700
125 USD
4 years ago
Oct 21, 2020
Sell 594 K USD
DEPPE MICHAEL J
VP, Corp. Controller & CAO
- 4750
125 USD
4 years ago
Oct 16, 2020
Sell 35 M USD
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
- 291997
120 USD
4 years ago
Oct 14, 2020
Sell 4.24 M USD
PREVOZNIK MICHAEL E
SVP & General Counsel
- 35591
119 USD
4 years ago
Sep 02, 2020
Sell 6.04 M USD
Doherty Catherine T.
SVP, Group Exec. Clin. Fran.
- 54616
110.567 USD
4 years ago
Sep 02, 2020
Sell 420 K USD
Doherty Catherine T.
SVP, Group Exec. Clin. Fran.
- 3776
111.127 USD
4 years ago
Jun 08, 2020
Sell 5.35 M USD
GUINAN MARK
Executive Vice President & CFO
- 45826
116.811 USD
4 years ago
Jun 08, 2020
Sell 2.15 M USD
GUINAN MARK
Executive Vice President & CFO
- 18246
117.649 USD
4 years ago
Jun 08, 2020
Sell 1.01 M USD
GUINAN MARK
Executive Vice President & CFO
- 8524
118.604 USD
4 years ago
Jun 08, 2020
Sell 1.37 M USD
RING TIMOTHY M
Director
- 11730
116.6 USD
4 years ago
Apr 27, 2020
Sell 1.31 M USD
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
- 11717
112.011 USD
4 years ago
Apr 27, 2020
Sell 280 K USD
EGLINTON MANNER CARRIE
SVP, Advanced Diagnostics
- 2500
112.03 USD
4 years ago
Apr 27, 2020
Sell 275 K USD
EGLINTON MANNER CARRIE
SVP, Advanced Diagnostics
- 2500
110 USD
4 years ago
Mar 16, 2020
Sell 17.1 K USD
Davis J. E.
EVP, General Diagnostics
- 200
85.59 USD
4 years ago
Mar 16, 2020
Sell 94 K USD
Davis J. E.
EVP, General Diagnostics
- 1085
86.654 USD
4 years ago
Mar 16, 2020
Sell 115 K USD
Davis J. E.
EVP, General Diagnostics
- 1307
87.813 USD
4 years ago
Mar 16, 2020
Sell 37.3 K USD
Davis J. E.
EVP, General Diagnostics
- 421
88.525 USD
4 years ago
Mar 16, 2020
Sell 45.1 K USD
Davis J. E.
EVP, General Diagnostics
- 500
90.146 USD
4 years ago
Mar 11, 2020
Sell 227 K USD
PREVOZNIK MICHAEL E
SVP & General Counsel
- 2175
104.25 USD
4 years ago
Mar 11, 2020
Sell 261 K USD
Doherty Catherine T.
SVP, Group Exec. Clin. Fran.
- 2501
104.25 USD
4 years ago
Mar 10, 2020
Sell 11.2 K USD
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
- 100
112.19 USD
4 years ago
Mar 06, 2020
Sell 19.2 M USD
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
- 171025
112.207 USD
4 years ago
Mar 06, 2020
Sell 4.18 M USD
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
- 36790
113.652 USD
4 years ago
Mar 06, 2020
Sell 1.88 M USD
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
- 16426
114.236 USD
4 years ago
Mar 06, 2020
Sell 455 K USD
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
- 3937
115.452 USD
4 years ago
Mar 06, 2020
Sell 233 K USD
RUSCKOWSKI STEPHEN H
Chairman, CEO and President
- 2000
116.272 USD
4 years ago
Feb 26, 2020
Sell 35.7 K USD
PREVOZNIK MICHAEL E
SVP & General Counsel
- 321
111.09 USD
4 years ago
Feb 27, 2020
Sell 75.2 K USD
PREVOZNIK MICHAEL E
SVP & General Counsel
- 690
109.02 USD
4 years ago
Feb 26, 2020
Sell 40.9 K USD
Doherty Catherine T.
SVP, Group Exec. Clin. Fran.
- 368
111.09 USD
4 years ago
Feb 27, 2020
Sell 86 K USD
Doherty Catherine T.
SVP, Group Exec. Clin. Fran.
- 789
109.02 USD
4 years ago
Feb 26, 2020
Sell 56.7 K USD
Davis J. E.
EVP, General Diagnostics
- 510
111.09 USD
4 years ago
Feb 27, 2020
Sell 120 K USD
Davis J. E.
EVP, General Diagnostics
- 1100
109.02 USD
4 years ago
Feb 25, 2020
Sell 67.4 K USD
Davis J. E.
EVP, General Diagnostics
- 598
112.73 USD
4 years ago
Feb 25, 2020
Sell 45.7 K USD
Doherty Catherine T.
SVP, Group Exec. Clin. Fran.
- 405
112.73 USD
4 years ago
Jan 02, 2020
Sell 6.14 M USD
Davis J. E.
EVP, General Diagnostics
- 58258
105.458 USD
4 years ago
Jan 02, 2020
Sell 791 K USD
Davis J. E.
EVP, General Diagnostics
- 7423
106.513 USD
4 years ago
Jan 02, 2020
Sell 7.28 M USD
Davis J. E.
EVP, General Diagnostics
- 69003
105.452 USD
4 years ago
Jan 02, 2020
Sell 943 K USD
Davis J. E.
EVP, General Diagnostics
- 8853
106.511 USD
4 years ago
Nov 27, 2019
Sell 1.27 M USD
PREVOZNIK MICHAEL E
SVP & General Counsel
- 11863
107.148 USD
7. News
Augurex Life Sciences and Quest Diagnostics Collaborate to Improve Rheumatoid Arthritis Diagnosis and Management VANCOUVER, British Columbia--(BUSINESS WIRE)-- #AxialSpondyloarthritis--Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced that it has formed a nonexclusive agreement with Quest Diagnostics, a leading provider of diagnostic information services, under which Quest will validate and offer a lab-developed test based on the Augurex 14-3-3η (eta) biomarker in the United States. Quest intends to begin offering the test service to physicians from its advanced laboratory in San Juan. businesswire.com - 1 day ago
All You Need to Know About Quest Diagnostics (DGX) Rating Upgrade to Buy Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 3 days ago
Is Quest Diagnostics Stock a Smart Addition to Your Portfolio Now? DGX exhibits strength in its base business. Increasing utilization of the Advanced Diagnostics offering is another positive. zacks.com - 4 days ago
Quest Diagnostics Declares Quarterly Cash Dividend SECAUCUS, N.J. , Nov. 12, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on January 29, 2025 to shareholders of record of Quest Diagnostics common stock on January 14, 2025. prnewswire.com - 4 days ago
DGX vs. PNTG: Which Stock Is the Better Value Option? Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Quest Diagnostics (DGX) and The Pennant Group, Inc. (PNTG). But which of these two companies is the best option for those looking for undervalued stocks? zacks.com - 5 days ago
Here's Why You Should Retain DGX Stock in Your Portfolio Now Investors feel optimistic about Quest Diagnostics' strength in Advanced Diagnostics. Robust base business volumes are also encouraging. zacks.com - 1 week ago
Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out? Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com - 3 weeks ago
Quest Diagnostics Has Massive Secular Tailwinds And A Strong Base Quest Diagnostics benefits from an aging population, driving increased lab testing volumes, particularly in genetic testing, and offers a 2.0% dividend yield. DGX's M&A strategy, including the LifeLabs acquisition, aims to expand its footprint and diversify operations, despite short-term EPS dilution. The company faces risks from PAMA reimbursement cuts and labor market challenges but expects long-term growth from organic and acquisition activities. seekingalpha.com - 3 weeks ago
Quest Diagnostics: Organic Growth Leads To Q3 Earnings Beat Quest Diagnostics reported strong Q3 earnings, with an 8.5% revenue increase and a 3.6% rise in diluted EPS, beating Street expectations. The company raised its 2024 revenue guidance and expects significant growth from recent and upcoming acquisitions, projecting double-digit revenue growth for Q4. Despite risks like economic downturns and inflation, I maintain a bullish outlook on DGX, adjusting my Buy Threshold to $150 and Sell Target to $227. seekingalpha.com - 3 weeks ago
DGX or PNTG: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Quest Diagnostics (DGX) or The Pennant Group, Inc. (PNTG). But which of these two companies is the best option for those looking for undervalued stocks? zacks.com - 3 weeks ago
4 Stocks to Buy in an Evolving Outpatient Home Health Industry Dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, EHC, AMED and ADUS are well-poised to gain. zacks.com - 3 weeks ago
US lab operator Quest Diagnostics to launch bird flu test at end of October Lab operator Quest Diagnostics said on Wednesday it will launch a test for H5N1 bird flu at the end of October after the U.S. Centers for Disease Control and Prevention (CDC) gave it contracts to support testing for two emerging infectious diseases, including the Oropouche virus. reuters.com - 3 weeks ago
8. Profile Summary

Quest Diagnostics Incorporated DGX

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 17.9 B
Dividend Yield 0.48%
Description Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Contact 500 Plaza Drive, Secaucus, NJ, 07094 https://www.questdiagnostics.com
IPO Date Dec. 17, 1996
Employees 50000
Officers Mr. Karthik Kuppusamy Ph.D. Senior Vice President of Clinical Solutions Ms. Catherine T. Doherty Executive Vice President of Regional Businesses Mr. Michael J. Deppe Senior Vice President, Corporate Controller & Chief Accounting Officer Ms. Kristin Lee Wallace Esq. Senior Vice President & Chief Compliance Officer Mr. Gary D. Samuels Senior Vice President & Chief Communications Officer Ms. Cecilia K. McKenney Senior Vice President & Chief Human Resources Officer Mr. James E. Davis Chairman, Chief Executive Officer & President Mr. Shawn C. Bevec Vice President of Investor Relations Mr. Murali Balakumar Senior Vice President, Chief Information & Digital Officer Mr. Sam A. Samad Executive Vice President & Chief Financial Officer